9 January 2019
EMA/916348/2019
EMEA/H/C/003925

Public statement

Taxespira

Withdrawal of the marketing authorisation in the European Union

On 30 October 2018, the European Commission withdrew the marketing authorisation for Taxespira (docetaxel) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Hospira UK Limited, which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Taxespira was granted marketing authorisation in the EU on 28 August 2015 for treatment of breast cancer, non small cell lung cancer, prostate cancer, gastric adenocarcinoma and head and neck cancer. The marketing authorisation was initially valid for a 5-year period.

Taxespira is a generic medicine of Taxotere. There are other generic medicinal products of Taxotere authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Taxespira will be updated to reflect the fact that the marketing authorisation is no longer valid.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5520
Send a question via our website www.ema.europa.eu/contact